Cargando…

Preparation of magnetic nanoparticle integrated nanostructured lipid carriers for controlled delivery of ascorbyl palmitate

Most cancer treatments can cause vital side effects on healthy tissues. Ascorbic acid (AA) is a water-soluble antioxidant molecule and possesses a variety of functions such as prevention of tumor proliferation and treatment of cancer. However, AA, is very sensitive to air, heat and light. Its high h...

Descripción completa

Detalles Bibliográficos
Autor principal: Kalaycioglu, Gokce Dicle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691729/
https://www.ncbi.nlm.nih.gov/pubmed/33294400
http://dx.doi.org/10.1016/j.mex.2020.101147
Descripción
Sumario:Most cancer treatments can cause vital side effects on healthy tissues. Ascorbic acid (AA) is a water-soluble antioxidant molecule and possesses a variety of functions such as prevention of tumor proliferation and treatment of cancer. However, AA, is very sensitive to air, heat and light. Its high hydrophilicity also makes the controlled delivery difficult. To overcome these problems, AA can be chemically-modified and made more hydrophobic by the esterification. Palmitic acid is one of the most common long-chain fatty acids that can be used for this purpose. It is known that Ascorbyl palmitate (AP) which is a lipopihilic derivative of AA, can inhibit cell proliferation and DNA synthesis in many types of cancer. Although AP has higher stability, its bioavailability and therapeutic effect is low due to its lipophilicity and low release capacity. • In this study, nanostructured lipid carriers (NLC) which are colloidal nanoparticles with high biocompatibility, low crystallinity and high hydrophobic-drug encapsulation capacity was prepared to increase the bioavailability of AP. • To provide triggered drug release via hyperthermia, magnetic nanoparticles (MNps) were integrated into the NLCs besides AP. • The synthesis of biocompatible NLCs with controlled and triggered release ability, is successfully completed and controlled release of AP as an antitumor agent is achieved.